
<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Document Content</title>
    <style>
        body { font-family: Arial, sans-serif; line-height: 1.6; max-width: 900px; margin: auto; padding: 20px; }
        table { border-collapse: collapse; width: 100%; margin-top: 20px; margin-bottom: 20px; }
        th, td { border: 1px solid #cccccc; text-align: left; padding: 8px; font-size: 12px; }
        tr:nth-child(even) { background-color: #f9f9f9; }
        th { background-color: #3366CC; color: white; font-weight: bold; }
        h2 { color: #4F81BD; border-bottom: 2px solid #4F81BD; padding-bottom: 5px;}
        p { margin-block-start: 0.5em; margin-block-end: 0.5em; }
    </style>
</head>
<body>
    <p style="font-size: small; color: grey;"><i>acad-10k 20171231.htm</i></p>
<p style="font-size: small; color: grey;"><i>Page 70 of 88</i></p>
<p style="font-size: small; color: grey;"><i>ACADIA_PHARMACEUTICALS_10k_070.pdf</i></p>
<p>ACADIA PHARMACEUTICALS INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands)</p>

<table>
	<tr>
		<th rowspan="2"></th>
		<th colspan="3">Years Ended December 31,</th>
	</tr>
	<tr>
		<th>2017</th>
		<th>2016</th>
		<th>2015</th>
	</tr>
	<tr>
		<td>Cash flows from operating activities</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Net loss</td>
		<td>$ (289,403)</td>
		<td>$ (271,393)</td>
		<td>$ (164,443)</td>
	</tr>
	<tr>
		<td>Adjustments to reconcile net loss to net cash used in operating activities:</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Stock-based compensation</td>
		<td>75,532</td>
		<td>55,265</td>
		<td>40,194</td>
	</tr>
	<tr>
		<td>Amortization of premiums and accretion of discounts on investment securities</td>
		<td>(291)</td>
		<td>89</td>
		<td>(2,060)</td>
	</tr>
	<tr>
		<td>Amortization of intangible assets</td>
		<td>1,477</td>
		<td>985</td>
		<td>—</td>
	</tr>
	<tr>
		<td>Depreciation</td>
		<td>1,236</td>
		<td>843</td>
		<td>647</td>
	</tr>
	<tr>
		<td>Income tax benefit from exercise of stock options</td>
		<td>—</td>
		<td>(596)</td>
		<td>(247)</td>
	</tr>
	<tr>
		<td>Loss on disposal of assets</td>
		<td>4</td>
		<td>5</td>
		<td></td>
	</tr>
	<tr>
		<td>Changes in operating assets and liabilities:</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Accounts receivable, net</td>
		<td>(11,440)</td>
		<td>(5,903)</td>
		<td>—</td>
	</tr>
	<tr>
		<td>Interest and other receivables</td>
		<td>150</td>
		<td>401</td>
		<td>(674)</td>
	</tr>
	<tr>
		<td>Inventory</td>
		<td>(1,012)</td>
		<td>(3,305)</td>
		<td>—</td>
	</tr>
	<tr>
		<td>Prepaid expenses and other current assets</td>
		<td>(911)</td>
		<td>(4,731)</td>
		<td>(804)</td>
	</tr>
	<tr>
		<td>Restricted cash</td>
		<td>(100)</td>
		<td>(2,000)</td>
		<td>(375)</td>
	</tr>
	<tr>
		<td>Other assets</td>
		<td>431</td>
		<td>(456)</td>
		<td>(42)</td>
	</tr>
	<tr>
		<td>Accounts payable</td>
		<td>4,874</td>
		<td>2,240</td>
		<td>(344)</td>
	</tr>
	<tr>
		<td>Accrued liabilities</td>
		<td>4,206</td>
		<td>15,579</td>
		<td>6,256</td>
	</tr>
	<tr>
		<td>Deferred revenue</td>
		<td>(2,644)</td>
		<td>2,644</td>
		<td>—</td>
	</tr>
	<tr>
		<td>Long-term liabilities</td>
		<td>34</td>
		<td>(75)</td>
		<td>97</td>
	</tr>
	<tr>
		<td>Net cash used in operating activities</td>
		<td>(217,857)</td>
		<td>(210,408)</td>
		<td>(121,795)</td>
	</tr>
	<tr>
		<td>Cash flows from investing activities</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Purchases of investment securities</td>
		<td>(478,818)</td>
		<td>(683,355)</td>
		<td>(269,486)</td>
	</tr>
	<tr>
		<td>Maturities of investment securities</td>
		<td>572,103</td>
		<td>430,937</td>
		<td>419,197</td>
	</tr>
	<tr>
		<td>Intangible assets</td>
		<td>—</td>
		<td>(8,000)</td>
		<td>—</td>
	</tr>
	<tr>
		<td>Purchases of property and equipment</td>
		<td>(812)</td>
		<td>(1,506)</td>
		<td>(2,141)</td>
	</tr>
	<tr>
		<td>Net cash provided by (used in) investing activities</td>
		<td>92,473</td>
		<td>(261,924)</td>
		<td>147,570</td>
	</tr>
	<tr>
		<td>Cash flows from financing activities</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Proceeds from issuance of common stock, net of issuance costs</td>
		<td>31,188</td>
		<td>518,896</td>
		<td>14,547</td>
	</tr>
	<tr>
		<td>Proceeds from settlement agreement</td>
		<td>—</td>
		<td>14,320</td>
		<td>—</td>
	</tr>
	<tr>
		<td>Deferred offering costs</td>
		<td>—</td>
		<td>—</td>
		<td>(292)</td>
	</tr>
	<tr>
		<td>Income tax benefit from exercise of stock options</td>
		<td>—</td>
		<td>596</td>
		<td>247</td>
	</tr>
	<tr>
		<td>Net cash provided by financing activities</td>
		<td>31,188</td>
		<td>533,812</td>
		<td>14,502</td>
	</tr>
	<tr>
		<td>Effect of exchange rate changes on cash</td>
		<td>(6)</td>
		<td>2</td>
		<td>7</td>
	</tr>
	<tr>
		<td>Net (decrease) increase in cash and cash equivalents</td>
		<td>(94,202)</td>
		<td>61,482</td>
		<td>40,284</td>
	</tr>
	<tr>
		<td>Cash and cash equivalents at beginning of period</td>
		<td>163,620</td>
		<td>102,138</td>
		<td>61,854</td>
	</tr>
	<tr>
		<td>Cash and cash equivalents at end of period</td>
		<td>$ 69,418</td>
		<td>$ 163,620</td>
		<td>$ 102,138</td>
	</tr>
	<tr>
		<td>Supplemental disclosure of cash flow information:</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Cash paid for income taxes</td>
		<td>$ 1,367</td>
		<td>$ 365</td>
		<td>$ 415</td>
	</tr>
	<tr>
		<td>Supplemental disclosure of noncash information:</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Property and equipment purchases in accounts payable and accrued liabilities</td>
		<td>$ 9</td>
		<td>$ 220</td>
		<td>$ 156</td>
	</tr>
	<tr>
		<td>Stock-based compensation capitalized in inventory</td>
		<td>$ (61)</td>
		<td>$ 870</td>
		<td>$ —</td>
	</tr>
</table>
<p>The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="font-size: small; color: grey;"><i>file://usmdcvdi003.us.kworld.kpmg.com/GDC_Ops/Operations/Gayathri%20Krishnan/RPA%20Phase%20II/Kiran/HealthCare/ ... 7/23/2018</i></p>
<p style="font-size: small; color: grey;"><i>F-5</i></p>

</body>
</html>
